Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-25-266895
Filing Date
2025-11-05
Accepted
2025-11-05 16:07:23
Documents
93
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q d920125d10q.htm   iXBRL 10-Q 2550924
2 EX-31.1 d920125dex311.htm EX-31.1 10374
3 EX-31.2 d920125dex312.htm EX-31.2 10359
4 EX-32 d920125dex32.htm EX-32 4344
  Complete submission text file 0001193125-25-266895.txt   13160835

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA teva-20250930.xsd EX-101.SCH 2197826
96 EXTRACTED XBRL INSTANCE DOCUMENT d920125d10q_htm.xml XML 2671549
Mailing Address TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV Israel
Business Address TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV Israel 972 (3) 914-8213
TEVA PHARMACEUTICAL INDUSTRIES LTD (Filer) CIK: 0000818686 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-16174 | Film No.: 251453944
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)